Dartmouth-Hitchcock logo
Medicine Grand Rounds - Diabetes & CVD: Have We Found the Holy Grail?

This presentation focuses on the results of clinical trials that are changing the management of Type 2 Diabetes and impacting the most recent treatment guidelines. It discusses the controversies surrounding diabetes therapies and their effects on cardiovascular disease, as well as the safety of new glucose lowering medications. There is detailed discussion of stepwise addition of glucose lowering drugs based on patient preferences, clinical considerations, co-morbidities and risks for specific adverse effects.

Activity Details

Start Date: August 3, 2018
End Date: August 3, 2020

You may claim CME credit for successful completion of this online course. In order to claim credit, you must follow these steps:

  1. Register for the learning activity by creating an account or logging in to your account.
  2. Click Continue to navigate to the Activity Material tab. Click View Presentation to view the recording.
  3. Return to this Activity page.
  4. Click Continue to navigate to the Evaluation tab; then click the Launch button to start the evaluation.
  5. Complete and Submit the evaluation and attestation form.

When the evaluation is submitted, you will be awarded credit. You may access your transcript for verification of participation at any time via Your Account. Need help? Visit the Support Page, send an Email, or call the Center for Learning and Professional Development at (603) 653-1234, Option 1.

  • Silvio E. Inzucchi, MD
    Professor of Medicine, Yale School of Medicine
    Clinical Chief of the Section of Endocrinology 
    Medical Director, Yale Diabetes Center

    Dr. Inzucchi received his undergraduate degree from Fordham University in New York City and his medical degree from Harvard Medical School in Boston, Massachusetts.  He completed his residency in Internal Medicine and his post-doctoral Fellowship in Endocrinology and Metabolism at Yale-New Haven Hospital, in New Haven, Connecticut. Dr. Inzucchi has been an invited lecturer both nationally and internationally on many topics, most pertaining to clinical diabetes management. His current research interests include pharmacological ant hyperglycemic therapy in both the inpatient and outpatient settings; and the link between type 2 diabetes, insulin resistance, and cardiovascular complications. He has held leadership roles in several large clinical trials related to diabetes medications and their cardiovascular impact. Dr. Inzucchi also has a large academic clinical practice involving a wide spectrum of patients with endocrine diseases, with a focus on diabetes and pituitary/adrenal diseases.

Learning Outcome

Participants will be able to discuss the link between diabetes and cardiovascular disease, including the results of key clinical trials that explore the benefits of glucose lowering, and glucose lowering drugs on cardiovascular disease outcomes and the impact these studies are having on diabetes treatment guidelines.


Dartmouth-Hitchcock is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Dartmouth-Hitchcock designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Requirements for Successful Completion

In order to receive credit for this Continuing Medical Education (CME) activity, you must:

  • View the entire presentation
  • Complete the online Attestation of Attendance & Evaluation Form (you must register to access).
Speaker Disclosure

In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.

The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for Diabetes & CVD: Have We Found the Holy Grail? (Medicine Grand Rounds) have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual’s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. All potential conflict(s) were resolved.

* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio. 

* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and has other financial interest from Takeda. 

* Silvio Inzucchi, MD ~ has grant/research support from NIDDK. He also is a consultant to Intarcia and VTV Therapeutics. Dr. Inzucchi has other financial interests with Boehringer Ingelheim, AstraZeneca, Sanofi/Lexicon, Novo Nordisk and Eisai.

Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.

There were no individuals in a position to control the content who refused to disclose.

*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.

Provider Contact Information

Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
Dartmouth-Hitchcock Medical Center

Type:     Internet Activity (Enduring Material)
20 Registered Users